You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

Drug Price Trends for NDC 68462-0421


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 68462-0421

Drug Name NDC Price/Unit ($) Unit Date
ATOVAQUONE 750 MG/5 ML SUSP 68462-0421-21 0.85429 ML 2024-12-18
ATOVAQUONE 750 MG/5 ML SUSP 68462-0421-69 0.85429 ML 2024-12-18
ATOVAQUONE 750 MG/5 ML SUSP 68462-0421-21 0.69840 ML 2024-11-20
ATOVAQUONE 750 MG/5 ML SUSP 68462-0421-69 0.69840 ML 2024-11-20
ATOVAQUONE 750 MG/5 ML SUSP 68462-0421-21 0.95547 ML 2024-10-23
ATOVAQUONE 750 MG/5 ML SUSP 68462-0421-69 0.95547 ML 2024-10-23
ATOVAQUONE 750 MG/5 ML SUSP 68462-0421-21 0.91959 ML 2024-09-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 68462-0421

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

68462-0421 Market Analysis and Financial Projection

Market Analysis and Price Projections for Atovaquone and Proguanil Hydrochloride (NDC: 68462-402-01)

Introduction

Atovaquone and proguanil hydrochloride, a combination drug used for the prophylaxis of Plasmodium falciparum malaria, is an essential medication for travelers and individuals living in malaria-endemic areas. This article provides a comprehensive market analysis and price projections for this drug, focusing on its current market status, pricing trends, and future outlook.

Current Market Status

Atovaquone and proguanil hydrochloride tablets are marketed under various NDC codes, including 68462-402-01, and are categorized as a human prescription drug with no DEA schedule classification[1].

Indications and Usage

The drug is indicated for the prophylaxis of Plasmodium falciparum malaria, including in areas where chloroquine resistance is present. This makes it a critical component in public health strategies to combat malaria.

Market Players

The drug is manufactured and distributed by several pharmaceutical companies, including Glenmark Pharmaceuticals Inc., USA. The presence of multiple manufacturers can influence pricing dynamics due to competition.

Pricing Trends

Historical Price Changes

While specific historical price data for atovaquone and proguanil hydrochloride is not provided in the sources, the broader context of prescription drug pricing in the U.S. is relevant. Many prescription drugs have seen significant price increases over the years, with some drugs experiencing increases ranging from 20% to 55% between 2018 and 2023[2].

International Price Comparisons

Prescription drug prices in the U.S. are generally higher than in other high-income countries. For example, U.S. manufacturer gross prices for brand-name drugs are approximately 422% of prices in comparison countries, although this gap can vary depending on the drug and market conditions[3].

Medicare Drug Price Negotiation Program

Impact on Pricing

The Medicare Drug Price Negotiation Program, part of the Inflation Reduction Act, aims to negotiate lower prices for high-expenditure drugs. While atovaquone and proguanil hydrochloride is not among the first 10 drugs selected for negotiation, the program's impact on the broader pharmaceutical market could indirectly affect pricing for other drugs.

Negotiated Prices and Savings

For drugs selected under this program, negotiated prices (Maximum Fair Prices) have resulted in significant discounts, ranging from 38% to 79% compared to list prices. This trend suggests that if atovaquone and proguanil hydrochloride were to be included in future negotiation cycles, similar discounts could be anticipated[5].

Price Projections

Short-Term Projections

In the short term, prices for atovaquone and proguanil hydrochloride are likely to remain stable or see moderate increases, consistent with general trends in prescription drug pricing. However, any changes in market conditions, such as increased competition or regulatory actions, could impact pricing.

Long-Term Projections

Long-term price projections are more speculative but can be informed by broader trends:

  • Regulatory Changes: Future inclusion in the Medicare Drug Price Negotiation Program or other regulatory initiatives could lead to significant price reductions.
  • Market Competition: Increased competition from generic or biosimilar alternatives could drive prices down.
  • Global Pricing: International price comparisons and global health initiatives may pressure U.S. prices to align more closely with those in other countries.

Key Factors Influencing Pricing

Demand and Supply

Demand for atovaquone and proguanil hydrochloride is driven by the need for malaria prophylaxis, particularly in travel and public health contexts. Supply chain disruptions or changes in demand due to global health trends can impact pricing.

Patent Status and Generic Competition

The presence of generic versions can significantly reduce prices. As patents expire, generic competition is likely to increase, leading to lower prices for consumers.

Regulatory Environment

Changes in regulatory policies, such as those related to drug pricing and negotiation programs, can have a profound impact on the pricing of prescription drugs.

Conclusion

The market analysis and price projections for atovaquone and proguanil hydrochloride indicate that while current prices may remain relatively stable, future trends are likely to be influenced by broader pharmaceutical market dynamics. Regulatory changes, increased competition, and global pricing pressures are key factors that could lead to significant price adjustments.

Key Takeaways

  • Atovaquone and proguanil hydrochloride is a critical drug for malaria prophylaxis.
  • U.S. prescription drug prices, including those for atovaquone and proguanil hydrochloride, are generally higher than in other countries.
  • Regulatory initiatives like the Medicare Drug Price Negotiation Program could lead to future price reductions.
  • Market competition and global pricing trends are likely to influence long-term price projections.

FAQs

Q: What is atovaquone and proguanil hydrochloride used for? A: Atovaquone and proguanil hydrochloride is used for the prophylaxis of Plasmodium falciparum malaria.

Q: Why are U.S. prescription drug prices higher than in other countries? A: U.S. prescription drug prices are higher due to various factors, including lack of price regulation, high research and development costs, and the presence of rebates and discounts that do not always benefit consumers directly[3].

Q: How does the Medicare Drug Price Negotiation Program affect drug prices? A: The program negotiates lower prices for high-expenditure drugs, resulting in discounts ranging from 38% to 79% compared to list prices[5].

Q: What factors influence the pricing of atovaquone and proguanil hydrochloride? A: Pricing is influenced by demand and supply dynamics, patent status, generic competition, and the regulatory environment.

Q: Are there any generic versions of atovaquone and proguanil hydrochloride available? A: Yes, generic versions are available, which can significantly reduce prices compared to the brand-name version[1].

Sources

  1. DailyMed: Atovaquone and Proguanil Hydrochloride tablet, film coated.
  2. ASPE - HHS.gov: Medicare Drug Price Negotiation Program.
  3. RAND: International Prescription Drug Price Comparisons: Estimates Using 2022 Data.
  4. DailyMed: Olmesartan Medoxomil tablet, film coated.
  5. CMS: Fact Sheet: Negotiated Prices Initial Price Applicability Year 2026.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.